Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
Teva Branded Pharmaceutical Products R&D, Inc. · Migraine
Phase 3
Completed
1,130
2021-11
Industry sponsor intelligence
Teva Branded Pharmaceutical Products R&D, Inc.Clinical Pipeline.
Lead-sponsor view of Teva Branded Pharmaceutical Products R&D, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 2
- Avg enrollment
- 1,003
Pipeline overview
Programs by phase and activity.
Velocity
Teva Branded Pharmaceutical Products R&D, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 20
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Calcitonin → | 2 | 0 | 0 | 2 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
Teva Branded Pharmaceutical Products R&D, Inc. · Migraine
Phase 3
Completed
875
2021-11
Search sponsor records
All Teva Branded Pharmaceutical Products R&D, Inc. studies.
This page groups studies where Teva Branded Pharmaceutical Products R&D, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT02621931Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic MigraineNov 9, 2021NCT02629861Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic MigraineNov 9, 2021